We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current NYMXF market cap is 23.54M. The company's latest EPS is USD -0.0726 and P/E is -2.75.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 299k | 116k | 5k | 0 | 0 |
| Operating Income | -10.64M | -13.33M | -11.72M | -12.5M | -6.65M |
| Net Income | -10.59M | -13.16M | -11.74M | -12.54M | -6.58M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 8.08M | 5.49M | 4.34M | 1.44M | 1.63M |
| Total Liabilities | 1.07M | 2.04M | 2.2M | 1.95M | 2.11M |
| Total Equity | 7M | 3.45M | 2.15M | -506k | -482k |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -7.8M | -7.43M | -10.04M | -9.82M | -5.21M |
| Investing | -36k | N/A | -13k | -6k | N/A |
| Financing | 14.93M | 4.72M | 8.42M | 7.05M | 5.78M |
| Market Cap | 23.54M |
| Price to Earnings Ratio | -2.75 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 12.9 |
| Price to Book Ratio | -37.56 |
| Dividend Yield | - |
| Shares Outstanding | 90.52M |
| Average Volume (1 week) | 18.95k |
| Average Volume (1 Month) | 20.55k |
| 52 Week Change | 116.67% |
| 52 Week High | 1.275 |
| 52 Week Low | 0.12 |
| Spread (Intraday) | 0.05 (16.13%) |
| Company Name | Nymox Pharmaceutical Corp (PK) |
| Address |
bay & deveaux sts., 2nd floor nassau H4M 2V2 |
| Website | https://www.nymox.com |
| Industry | chemicals & chem preps, nec (2899) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
